Median Technologies Expands AI Lung Cancer Screening in Europe
SOPHIA ANTIPOLIS, France, July 2, 2026 Median Technologies has announced that its eyonis® LCS, an artificial intelligence (AI)-powered Software...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOPHIA ANTIPOLIS, France, July 2, 2026 Median Technologies has announced that its eyonis® LCS, an artificial intelligence (AI)-powered Software...
PALO ALTO, California, May 28, 2026 DELFI Diagnostics has achieved a significant regulatory milestone after receiving a Clinical Laboratory...
PALO ALTO, Calif., May 13, 2026 DELFI Diagnostics announced that it will present the first-ever clinical utility data for...
